An important practical question from VOLGA:

Radical cystectomy completion: 85% with EV/durvalumab vs 78% control.

But only 55% completed adjuvant treatment.

How much benefit comes from the neoadjuvant phase, and can we identify patients who need postoperative therapy? #ESMO26